Greenwich LifeSciences, Inc. (GLSI)
| Market Cap | 168.91M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.50M |
| Shares Out | 13.14M |
| EPS (ttm) | -0.81 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 30,266 |
| Open | 12.84 |
| Previous Close | 12.77 |
| Day's Range | 12.64 - 13.31 |
| 52-Week Range | 8.00 - 21.44 |
| Beta | 3.32 |
| Analysts | Strong Buy |
| Price Target | 38.00 (+195.72%) |
| Earnings Date | Nov 14, 2024 |
About GLSI
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford,... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for GLSI stock is "Strong Buy" and the 12-month stock price forecast is $38.0.
News
Greenwich LifeSciences Provides Update on Corporate Events
STAFFORD, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an im...
Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain
STAFFORD, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAM...
Greenwich LifeSciences: Halting Of Breast Cancer Recurrence With GLSI-100
Greenwich LifeSciences, Inc. approaches enrollment completion for the phase 3 Flamingo-01 study, using GLSI-100 for the treatment of patients with HER2/neu positive breast cancer, with full enrollment...
Greenwich LifeSciences Set to Join Russell 2000 Index Again
STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAM...
Greenwich LifeSciences Announces $2.5 Million Private Placement
STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company" or "Greenwich"), a clinical-stage biopharmaceutical company focused on its Phase III clini...
Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025
STAFFORD, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLA...
Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe
STAFFORD, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLA...
Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries
STAFFORD, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flam...
Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators
STAFFORD, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flam...
Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01
STAFFORD, Texas, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an im...
Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024
STAFFORD, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an im...
Greenwich LifeSciences Provides Year End Update
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to ...
Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to ...
Greenwich LifeSciences: Persevering CEO And Interesting Data
Greenwich LifeSciences, Inc. is a one-man, one-asset shop. The asset, GP2, has produced excellent breast cancer data.
Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial
Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial
Greenwich LifeSciences Provides Financing Strategy & Corporate Update
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Financing Strategy & Corporate Update
Here's Why Greenwich Lifesciences Shares Are Popping Off Today
Greenwich Lifesciences Inc (NASDAQ: GLSI) shares are trading higher by 32.95% to $11.46 Tuesday afternoon after the FDA removed the clinical hold on the company's Flamingo-01 Phase 3 trial of GP2. Gre...
Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed
Greenwich LifeSciences Announces Suspension of Share Repurchase Program
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Suspension of Share Repurchase Program
Greenwich LifeSciences to Resume Stock Repurchase Program
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Resume Stock Repurchase Program
Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting
Greenwich LifeSciences: A First Look
Shares of Greenwich LifeSciences, Inc. are trading near their lowest levels since the stock exploded upward in December 2020 in what was an illustrative example of an inefficient market. A still-pendi...
Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential
Greenwich LifeSciences is a stock relatively new to the market and lesser-known, as it became public in September of 2020. Not long after, the stock skyrocketed over 1000% on early data that the compa...
Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences